Compounds and methods for the inhibition of the expression of VCAM-1
AssigneeAtheroGenics, Inc.
InventorCharles Q. Meng
Life of this patent
Estimating the term…
Abstract
This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
Claims26
A compound of the formula
- or a pharmaceutically acceptable salt or ester thereof.
A compound of the formula
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of the formula
- together with a pharmaceutically acceptable carrier.
A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A method for the treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A method for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.